Related Experiment Videos
[The curative effects of anti-TNF monoclonal antibody in E. coli infected mice]
Objective:
To evaluate effects of monoclonal antibody (McAb) against TNFa on E. coli infected mice.
Methods:
30 mice (10 week old, Kunming) were divided equally into three groups. The first group, as a control, 200 microliters saline (NS)/mouse was injected intravenously; Second group (untreated group), only E. coli (10(7) organisms/200 microliters NS) were injected intra-abdominaly; Third group (treated group), E. coli (10(7) organisms) were injected intra-abdominal and McAb against TNF alpha 2 mg/kg dissolved in 200 microliters NS were injected intravenously. After 24 h, observed the survival rate, compared the serum TNF level in blood and investigated pathology of intestine, lung and liver.
Results:
There was a higher survival rate in treated group, with the serum TNF level lowered significantly, and the untreated mice had severe pathologic changes in viscera.
Conclusion:
Using anti-TNF alpha McAb was effective in reducing mortality rate in mice after infected with E. coli, but could not prevent the pathologic changes.
Insights
Monoclonal antibody (McAb) against tumor necrosis factor alpha (TNFa) improved survival rates in E. coli infected mice by reducing TNFa levels. However, it did not prevent severe pathological changes in organs.
Area of Science:
- Immunology
- Microbiology
- Pathology
Context:
- Bacterial infections, such as E. coli, pose significant health risks.
- Tumor necrosis factor alpha (TNFa) plays a critical role in the inflammatory response to infection.
- Monoclonal antibodies (McAbs) are a class of therapeutic proteins that can target specific molecules.
Purpose:
- To investigate the therapeutic efficacy of a monoclonal antibody targeting TNFa in a mouse model of E. coli infection.
- To evaluate the impact of anti-TNFa McAb on survival rates, serum TNFa levels, and organ pathology.
Summary:
- Mice infected with E. coli were treated with either saline, E. coli alone, or E. coli plus anti-TNFa McAb.
- The anti-TNFa McAb treatment group exhibited increased survival rates and significantly lower serum TNFa levels compared to the untreated group.
- While mortality was reduced, severe pathological alterations in the intestine, lung, and liver were still observed in the treated mice.
Impact:
- Anti-TNFa McAb demonstrates potential as an adjunctive therapy to reduce mortality in E. coli infections.
- Further research is needed to address the persistent organ damage despite reduced TNFa levels.
- This study contributes to understanding the complex role of TNFa in bacterial pathogenesis and host response.